A case report of immunotherapy on a patient with advanced gastric cancer by adoptive transfer of OK-432-reactive HLA-matched allogeneic lymphocytes

Cancer Immunology Immunotherapy

Volumn 46, Issue 2, 1998, Pages 113-119

  Yamagishi, Hisakazu ^a   Ueda, Yuji ^a   Oka, Takahiro ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Adoptive immunotherapy; Allogeneic cell therapy; Gastric cancer; Interleukin 2 (IL 2); OK 432

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; HLA ANTIGEN; INTERLEUKIN 2; PICIBANIL;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CASE REPORT; CELL TRANSPLANTATION; HLA TYPING; HUMAN; LYMPHOCYTE; MALE; PRIORITY JOURNAL; SIBLING; STOMACH CANCER; TREATMENT OUTCOME;

ADENOCARCINOMA, SCIRRHOUS; ADULT; FATAL OUTCOME; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES; MALE; PICIBANIL; STOMACH NEOPLASMS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0031967412     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050469     Document Type: Article

References (24)

1. Berd D, Mastrangelo MJ, Engstrom PF, Paul A, Maguire H (1982) Augmentation of the human immune response by cyclophosphamide. Cancer Res 42:4862
2. Celis E, Tsai V, Crimi C, Demars R, Wentworth PA, Chesnut RW, Grey HM, Sette A, Serra HM (1994) Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA 91:2105
3. Ito K, Yoshida H, Yanagibashi K, Shimada Y, Imamura M, Tobe T, Akiyama Y, Saji H, Maruya E, Hosoi T (1988) Change of HLA phenotype in postoperative erythroderma. Lancet I:413
4. Kahan BD, Pellis NR, Legrue SJ, Tanaka T (1982) Immunotherapeutic effects of tumor-specific transplantation antigens released by 1-Butanol. Cancer 49:1168
5. Kimoto Y, Tanaka T, Tanji Y, Fujiwara A, Taguchi T (1994) Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies. Biotherapy (Dordr) 8:41
6. Kirkwood JM, Wilson J, Whiteside TL, Bryant J, Doemelly S, Herberman RB (1997) Phase IB trial of picibanil (OK-432) as an immunomodulator in patients with resected high-risk melanoma. Cancer Immunol Immunother 44:137
7. Kohler PC, Hank JA, Exten R, Minkoff DZ, Wilson DG, Sondel PM (1985) Clinical response of a patient with diffuse histiocytic lymphoma to adoptive chemoimmunotherapy using cyclophosphamide and alloactivated haploidentical lymphocytes. A case report and phase I trial. Cancer 55:552
8. Maehara Y, Okuyama T, Kakeji Y, Baba H, Furusawa M, Sugimachi K (1994) Postoperative immunochemotherapy including streptococcal lysate OK-432 is effective for patients with gastric cancer and serosal invasion. Am J Surg 168:36
9. Margolin KA, Rayner AA, Hawkins MJ, Atkins MB, Dutcher JP, Fisher RI, Weiss GR, Doroshow JH, Jaffe HS, Roper M, Parkinson DR, Wiernik PH, Creekmore SP, Boldt DH (1989) Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol 7:486
10. Nakao M, Yamana H, Imai Y, Toh Y, Tou U, Kimura A, Yanoma S, Kakegawa T, Itoh K (1995) HLA A2601-restricted CTLs recognize a peptide antigen expressed on squamous cell carcinoma. Cancer Res 55:4248
11. Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J (1994) Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet 343:1122
12. Okuno K, Kobayashi S, Jinnai H, Lee YS, Shigeoka H, Yasutomi M (1996) IL-2 perfusion to the liver augments the hepatic extraction rate of accompanying anticancer drugs. Surg Today 26:662
13. Ozaki S, Suginoshita T, Watanabe T, Obayashi H (1990) Mechanism of tumoricidal activity of OK-432-specific L3T4+Lyt2-T cells. Cancer Res 50:4630
14. Ozaki S, Okazaki T, Nakao K (1995) Biological response modifiers (BRM) as antigens III. T cell lines specific for BRM kill tumor cells in a BRM-specific manner. Cancer Immunol Immunother 40:219
15. Petrovsky N, Harrison LC (1995) Cytokine-based human whole blood assay for the detection of antigen-reactive T cells. J Immunol Methods 186:37
16. Rosenberg SA (1992) The immunotherapy and gene therapy of cancer. J Clin Oncol 10:180
17. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwarzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE (1994) Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2. J Natl Cancer Inst 86:1159
18. Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J, Brautbar C, Or R (1996) Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 87:2195
19. Sondel PM, Hank JA (1981) Alien-driven diversity and alien-selected escape: A rationale for allogeneic cancer immunotherapy. Transpl Proc 13:1915
20. Sondel PM, Hank JA, Wendel T, Flynn B, Bozdech MJ (1983) HLA identical leukemia cells and T cell growth factor activate cytotoxic T cell recognition of minor locus histocompatibility antigens in vitro. J Clin Invest 71:1779
21. Starzl TE, Demetris AJ, Murase N, Ildstad S, Ricordi C, Trucco M (1992) Cell migration, chimerism, and graft acceptance. Lancet 339:1579
22. Toh Y, Yamana H, Shichijo S, Fujita H, Tou U, Sakaguchi M, Kakegawa T, Itoh K (1995) Expression of MAGE-1 gene by esophageal carcinomas. Jpn J Cancer Res 86:714
23. Verdonck LF, Lokhorst HM, Dekker AW, Nieuwenhuis HK, Petersen EJ (1996) Graft-versus-myeloma effect in two cases. Lancet 347:800
24. + T cell activity. J Immunol 148:648